ISSN:
0730-2312
Keywords:
4-HPR
;
bladder cancer
;
chemoprevention
;
DNA flow cytometry
;
intermediate endpoints
;
retinoids
;
Life and Medical Sciences
;
Cell & Developmental Biology
Source:
Wiley InterScience Backfile Collection 1832-2000
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
Notes:
The ability ofthesynthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) to affect the outcome of previously resected superficial bladder cancer was investigated in apilot study using DNA content flow cytometry and conventional cytology as intermediate endpoints. Twelve patients were treated with oral 4-HPR (200 mg daily) and compared with 17 non-randomized, untreated controls. The median interval between transurethral resection and 4-HPR administration was 5.5 months (rangs 0-36). The median follow-up period was 12 months (rang 3-31) in the4-HPR group and 9 months (range 2-22) in the control group. The proportion of patients with DNA aneuploid stemlines in bladder-washed cells decreased form 7/12 (58%) to5/11 (45%) in the 4-HPR group, but increased form 7/17 (41%) to 10/17(59%) in the control group. In patients with stable diploid profiles, mean (±SE) S-phase and G2-M-phase fractions decreased in the course of retinoid treatment from basal levels of 15.2±4.1% to 7.5±3.3% and 10.3±2.2% to 5.2 ±0.4%, respectively. The same parameters in the control group changes from basal levels of 14.6±3.4% to 12.4±2.7% and 9.8±1.6% to 12.6±1.6%, respectively. Positive or suspicious cytologic examinations were present in 3/12 (25%) treated cases prior to 4-HPR) administration and all subsequently reverted to normal. The same parameter in the control group increased from 4/17 (24%) to 6/17 (35%)during follow-up. Impaired adaptation to darekness was recorded in 4 patients, and transient dermatologic alterations were observed in one-third of the patients, requiring dose reduction in one case. Our preliminary data suggest that4-HPR may affect theDNA content and abnormal cytology in patients with previously resected superficial bladder cancer. © 1992 Wiley-Liss, Inc.
Additional Material:
2 Ill.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1002/jcb.240501327
Permalink
